Dr. Jules JE Doré, PhD
Associate Professor, Assistant Dean of Graduate Studies; Faculty of Medicine
Faculty of Medicine, Memorial University of Newfoundland
TGF-beta, signal transduction, cell cycle regulation
Transforming growth factor beta converts from a growth inhibitor to a promoter in cancer
During the transformation of normal cells to epithelial cancers the main hormone used to inhibit growth, TGF-beta, loses this ability. Worse, it becomes a stimulator of growth. My research is looking into how, inside a cancer cell, the signalling gets switched to make this happen. Recently we have zeroed in on the control of the activation of the Erk signalling pathway as one of the ways that prostate and ovarian cancers might be making the switch.
Involvement with BHCRI to date:Dr. Doré is a BHCRI Senior Scientist and has been a member of a BHCRI Scientific Review Committee.
Contact:Rm 5329, HSC, Memorial University of Newfoundland, St. John’s, NL, A1B 3V6
Zhai G, J Doré and P Rahman. (2015). TGF-β signal transduction pathways and osteoarthritis. Rheumatol Int, 35(8):1283-92.
Hough, C, M Radu, JJ Doré. (2012). TGF-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS One, 7(8):e42513.
Shaker MA , N Daneshtalab, JJE Doré and HM Younes. (2010). Biocompatibility and biodegradability of implantable drug delivery matrices based on novel poly
(decane-co-tricarballylate) photocured elastomers. J Bioactive Compatible Polymers, 27(1):78-94.
White NM, M Mathews, GM Jousef, A Prizada, D Fontaine, P Ghatage, P Popadiuk, L Dawson and JJE Doré. (2009). Human kallikrein related peptidases 6 and 13 in
combination with CA125 is a more sensitive test for ovarian cancer than CA125 alone. Cancer Biomarkers, 5:279-87.